Introduction
============

Lyme disease is caused by the spirochetal bacteria, *Borrelia burgdorferi,* and is transmitted by ticks of the genus Ixodes [@B1]. Invasion of the mammalian host by *B. burgdorferi* results in the release of inflammatory mediators and the influx of inflammatory cells in multiple organs such as the skin, heart, joints, and central and peripheral nervous systems [@B2]-[@B5]. Arthritis is one of its most important features and also is the most distinguishing feature of late-stage Lyme disease [@B5], [@B6]. The mechanism by which *B. burgdorferi* induces joint damage is only partially understood. Considering Lyme arthritis is known to progress relatively slowly [@B7], [@B8], it is thought that inflammation, induced either by the spirochete or by the spirochetal antigens left in tissues after bacterial demise, plays a major role in disease pathogenesis [@B9].

BmpA is a member of the paralogous Bmp protein family, which is encoded by the tandemly arrayed bmp genes on the linear *B. burgdorferi* chromosome and located in the outer membrane surface of spirochetes as membrane lipoproteins [@B10]. It is also highly immunogenic in human beings and animals and is one of the antigens used in serodiagnostic tests for Lyme disease [@B11]. Our previous study found that the *B.burgdorferi* basic membrane protein A (BmpA) is involved in the genesis of Lyme arthritis [@B11]. The BmpA gene of Lyme-causing spirochetes was preferentially up-regulated in mouse joints compared with other organs, and *B. burgdorferi* lacking BmpA failed to induce arthritis [@B11]. Research on BmpA may help promote understanding of *B. burgdorferi* pathogenesis and provide an important basis for diagnosis and treatment of Lyme disease.

Lyme disease occurs with both the innate immune and the adaptive immune responses [@B12]. The knee joints suffer more often, and the pathological manifestations of the lesion were monocytic infiltration, synovial hypertrophy, and vascular dilation [@B13]. Chemokines play an important role in innate and adaptive immunities via mediation of inflammatory cell chemotaxis and the release of inflammatory mediators; they have a close relationship with acute and chronic inflammatory diseases [@B14]. In recent years, with the thorough study of Lyme disease and Lyme arthritis, results have shown that chemokines could be key mediators in Lyme disease. When comparing chemokine secretion levels in arthritis-susceptible mice (C3H mice) and tolerant mice (C56BL mice) after spirochete ankle joint inoculation, the results showed that the neutrophil chemokine KC (CXCL1) and monocyte chemotactic factor MCP-I (CCL2) were overexpressed in the C3H mice infected with *B. burgdorferi.* This caused monocyte and neutrophil invasion of the joint tissue, which led to arthritis [@B15]. Other animal model studies also showed that C3H mice deficient in TLR2 infected with *B. burgdorferi*, the chemokines CXCL9 and 10 are expressed in large amounts in mouse joints, thus attracting mononuclear and other inflammatory cells to infiltrate to the joints and resulting in the occurrence of Lyme arthritis [@B16]. In addition, in a study on chemokine levels of synovial fluid samples in 49 Lyme arthritis patients, the authors found that 33 antibiotic-resistant patients had much higher chemokine levels in their synovial fluid samples [@B17]. Researchers also studied proliferation of peripheral blood mononuclear cells (PBMC) and CD14^+^ monocytes/macrophages in patients with Lyme arthritis. The results showed that *B. burgdorferi-* stimulated cells could induce the production of chemokines CCL2 and 4 and CXCL9 and 10, which was statistically significantly different compared with unstimulated cells. The results also indicated that *B. burgdorferi* could directly stimulate monocyte- macrophages to secrete a large number of chemokines, which revealed that inherent immune responses play an important role in early and late Lyme disease. On the other hand, *B. burgdorferi* could stimulate other cells (such as natural killer \[NK\] cells) to produce interferon-γ and indirectly induce T cells to gather in the joint tissue, which then initiates an adaptive immune response in the body [@B18]. In summary, chemokines are closely related to the occurrence of Lyme arthritis, which mediates the innate immune response and participates in adaptive immune responses. This study aimed to differentially sort out key expressed chemokines after murine macrophages were stimulated with rBmpA and to explore the potential role of *B. burgdorferi* dominant proteins during Lyme arthritis pathogenesis.

Materials and methods
=====================

rBmpA Preparation
-----------------

The recombinant BmpA (rBmpA) was produced in *E. coli* using the bacterial expression vector pGEX-6P1 (GE, USA) and the following primers with *EcoR*Ⅰand *Xho*Ⅰ restriction sites (5-3)ACG AAT TCA TGA ATA AAA TAT TGT TGT TGA, AGC TCG TAA ATA AAT TCT TTA AGA AA [@B19]. Expression, purification, and enzymatic cleavage of glutathione transferase fusion protein and rBmpA harvest were carried out as previously described [@B20]. Lipopolysaccharide (LPS) and phorbol-12-myristate-13-acetate were purchased from Sigma- Aldrich (USA), and ionomycin was purchased from Apollo (USA).

Cell cultures
-------------

The murine macrophage cell line, RAW264.7, was obtained from Kunming Institute of Zoology, Chinese Academy of Sciences (Kunming, China). Cell culture supplies were obtained from Gibco, Life Technologies (USA). The cells were maintained at 37 ℃, 5% CO a~2~ and cultured in high-glucose Dulbecco\'s modified Eagle medium with 10% fetal bovine serum, 10000 U/ml penicillin, and 10 mg/ml streptomycin. For rBmpA stimulation test, RAW264.7 cells were seeded in 96-well microplates at a concentration of 8×10^4^ \~ 1×10^5^/ml and stimulated with 10 μg/ml rBmpA and 20 μg/ml rBmpA. Other cells were also maintained in the medium as blank controls and stimulated with 1μg/ml LPS as positive controls. Cellular supernatants were collected 12, 24, and 48 h post-stimulation and stored at -80 ℃ until used for antibody high-throughput microarray analysis and enzyme-linked immunosorbent assay (ELISA). Cell lysates were prepared using the RNAiso Plus reagent (Takara, Japan) and stored at -80℃ until used for RNA extraction.

High-throughput Detection of chemokines
---------------------------------------

Twenty-five chemokines in cell culture supernatants from RAW264.7 cells at 12 and 24h post- stimulation with rBmpA were detected by chemokine protein microarray technology (RayBiotech, Inc.) in order to sort out highly expressed chemokines.

RNA Extraction and Real-time Quantitative PCR
---------------------------------------------

mRNA expressions of MCP-5/CCL12 and MIP-2/CXCL2 were assessed by quantitative real-time PCR (qPCR). Total RNA was extracted from cells using the RNAiso Plus reagent (TaKaRa, Japan) according to the manufacturer\'s instructions. Prime Script RT reagent Kit with gDNA Eraser (TaKaRa, Japan) was used to synthesize cDNA according to the manufacturer\'s protocol. Relative gene expression levels were calculated using the comparative threshold-cycle method of quantitative PCR with data normalized to the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Specific primer sequences used to amplify murine MCP-5/ CCL12, MIP-2/CXCL2 and GAPDH consisted pf several primers: murine MCP-5 (forward: 5\'- TTC CAC ACT TCT ATG CCT GC -3\', reverse: 5\'- CTG GCT TGT GAT TCT CCT GT -3\'), murine MIP-2 (forward: 5\'- CAC TCT CAA GGG CGG TCA AA -3\', reverse: 5\'- GCT CCT TTC CAG GTC AGT TA -3\'), murine GAPDH (forward: 5\'- TCC CAG AGC TGA ACG GGA AG-3\', reverse: 5\'- TCA GTG GGC CCT CAG ATG C -3\'). qPCR was performed using the SYBR Premix Ex Taq (TaKaRa, Japan) according to the manufacturer\'s protocol. The total volume used in the PCR reaction was 20 μl.

ELISA
-----

Highly expressed MCP-5/CCL12 and MIP-2/ CXCL2 in the microarray were chosen for additional studies. The MCP-5/CCL12 and MIP-2/CXCL2 concentrations of all cell supernatant samples were measured using the ELISA method. The ELISA was performed using Mouse MCP-5 ELISA Kit Mouse MIP-2 ELISA kit (RayBiotech, Inc. Guangzhou,China) according to the manufactures\' protocols.

Statistical analysis
--------------------

Results were expressed as the mean ± SEM. The significance of the difference between the mean values of the groups was evaluated by one-way analysis of variance method of square-deviation using the statistical analysis software GraphPad Prism 6.0. Differences were considered statistically significant at a value of P \<0.05.

Results
=======

Murine microarrays sorted out several highly expressed chemokines
-----------------------------------------------------------------

When compared with the blank control group, rBmpA can stimulate the mouse macrophage cell line RAW264.7 cells to secrete a variety of chemokines. LPS and 10 and 20μg/ml rBmpA induced higher level of 23 kinds of chemokines found in the supernatant from murine macrophages both 12 and 24 h post-stimulation. The secretion levels of MCP-5/CCL12 and MIP-2/CXCL2 also increased significantly. Thus, we chose MCP-5/CCL12 and MIP-2/CXCL2 for further study (Table [1](#T1){ref-type="table"}).

RT-PCR confirmed higher expression of MCP-5/CCL12 and MIP-2/CXCL2
-----------------------------------------------------------------

MCP-5 (CCL12) mRNA expression levels in murine macrophages were detected in each sample. As shown in Figure [1](#F1){ref-type="fig"}, relative expression levels of MCP-5 (CCL12) were significantly higher in both LP S- and 10 and 20μg/ml rBmpA-treated cells than in the blank control at 12 and 24 h post-stimulation (P \<0.01). The differences at the 48-h time point did not reach significance, however, when compared to the control. rBmpA up-regulated the expression of the MCP-5 gene in mouse macrophage RAW264.7 cells at the 12 and 24 h time points, but after longer stimulation periods with rBmpA, the MCP-5 gene expression level gradually decreased (Figure [1](#F1){ref-type="fig"}).

*MIP-2/CXCL2* mRNA expression levels in murine macrophages were detected in each sample.*MIP-2/CXCL2* relative expression levels were significantly higher in murine macrophages induced by LPS and 10and 20μg/ml rBmpA than in blank controls 12, 24, and 48 h post-stimulation (P \<0.01). With the exception of no significant differences between 10μg/ml rBmpA and controls at the 48-h time point (P \>0.05), rBmpA up-regulated the expression level of MIP-2 gene in murine macrophage cells in a concentration-dependent manner. However, at the longer period of rBmpA time stimulation, the expression level of MIP-2 gene in cells decreased gradually (Figure [2](#F2){ref-type="fig"}).

ELISA confirmed higher secretion of MCP-5/CCL12 and MIP-2/CXCL2
---------------------------------------------------------------

The MCP-5 (CCL12) concentrations were quantified using the ELISA at different culture time points (12, 24, and 48 h). Compared with the blank control group, LPS and 10 and 20 μg/ml rBmpA induced significantly higher MCP-5 (CCL12) levels in the supernatant from murine macrophages at 12, 24, and 48 h post-stimulation (P \<0.01). MCP-5 (CCL12) concentrations after LPS treatment were 311.025±44.268, 1156.345±124.827, and 2706.576± 586.054 pg/ml at 12, 24, and 48 h, respectively. After 10 μg/ml rBmpA treatment, MCP-5 levels were 58.660±4.569, 54.556±8.426, and 76.901±5.411 pg/ml at 12, 24, and 48 h post-stimulation, respectively and after 20μg/ml rBmpA, the levels were 84.867±1.592, 157.962±20.564, and 168.014±22.489 pg/ml at 12, 24, and 48 h post-stimulation, respectively. With the increase in rBmpA concentrations, MCP-5 in cell culture supernatants showed a concentration-dependent increase (p \<0.01). The chemokine MCP-5 expression levels in RAW264.7 cells was up-regulated in a time-dependent manner with the same dose of rBmpA, and the difference was statistically significant (p \<0.01). The results showed that with the increase of rBmpA concentration and increase in stimulation period, the amount of MCP-5 in RAW264.7 cells increased to varying levels (Figure [3](#F3){ref-type="fig"}).

ELISA was used to quantify MIP-2/CXCL2 concentrations at different stimulation time points (12, 24, and 48h). Compared with the normal control group, LPS and 10 and 20 μg/ml rBmpA induced significantly higher MIP-2/CXCL2 levels in the supernatant from murine macrophages 12, 24, and 48h post stimulation (P \<0.01). MIP-2/CXCL2 concentrations after LPS treatment were 14863.7±214.531, 18219.0±334.34, and 40314.0±383.946 pg/ml at 12, 24, and 48 h, respectively. After treatment with 10μg/ml rBmpA, MIP-2/CXCL2 concentrations were 221.445±10.784, 203.072±21.838, and 767.365±38.3 7 pg/ml at 12, 24, and 48 h post-stimulation, respectively, and after 20μg/ml rBmpA treatment, levels were 451.215±9.488, 422.085±13.8, and 1453.125±101.02 pg/ml at12, 24, and 48 h post stimulation, respectively (Figure [4](#F4){ref-type="fig"}).

Discussion
==========

Lyme disease is a global epidemic disease, which is widely distributed, rapidly spread, and causes a high disability rate. It has become a global health issue, which has attracted a lot of attention from the medical community. Lyme arthritis is the main form of Lyme disease, which is one of the most harmful effects of Lyme disease. Without appropriate antibiotic therapy, approximately 60% of the infected patients develop Lyme arthritis [@B21].

BmpA protein, as the product of *B. burgdorferi* gene *bmpA* and one of *B. burgdorferi* \'s main antigens, plays a key role in Lyme arthritis [@B22]. In an effort to understand how BmpA stimulates murine macrophage cells to secrete chemokines, the murine macrophage cell line RAW264.7 was incubated with BmpA or LPS, and the levels of chemokines were measured in culture supernatants. LPS acts as the positive control of this experiment, and as the quality control standard of this experiment, its concentration was 1 ug/ml [@B19], [@B23]-[@B25]. A study reported that *B.burgdorferi* directly stimulated CD14+ monocytes to secrete CCL4, a chemoattractant for monocytes and some T cells [@B26]. In addition, Strle et al. demonstrated that *B. burgdorferi* induced macrophages directly to secrete CXCL8, a neutrophil chemoattractant, and CCL3, a chemoattractant for monocytes, and natural killer (NK) and T cells [@B27]. These chemokines appear to be important for the innate immune responses to *B. burgdorferi* [@B28].

In this study, using chemokine array, we demonstrated that rBmpA stimulated mouse macrophage RAW264.7 cells to overexpress the chemokines MCP-5 and MIP-2, mRNA expression and protein secretion, found that association between these chemokines and rBmpA concentration were positive related. The chemokine MCP-5(CCL12), which is derived from macrophages, mast cells, fibroblasts, and endothelial cells and has a chemotactic effect on monocytes. T lymphocytes and NK cells that belong to the CC type chemokine family can induce granulocytes to release biologically active agents. A large number of experimental studies have shown that CC chemokines have different degrees of expression in inflammatory-related diseases such as rheumatoid arthritis, acute pancreatitis, and autoimmune diseases [@B29]. The chemokine MIP-2 (CXCL2) belongs to the CXC type of chemokines and can attract neutrophil aggregation at the inflammatory tissue site. Furthermore, MIP-2 is also one of the chemokines that are closely associated with inflammatory diseases such as acute pancreatitis [@B29]. Since Lyme arthritis shows pathological changes consisting of synovial hyperplasia, vascular dilatation, and mononuclear cell infiltration, the chemokines MCP-5 and MIP-2 appear to be responsible for promoting neutrophil, monocyte, and other inflammatory cell aggregation at the infection site; therefore, combined with the characteristics of Lyme arthritis and reference antibody chip detection results and in order to further explore the action mechanism of the chemokines in rBmpA induced Lyme arthritis, we selected the MCP-5/CCL12 and MIP-2/CXCL2 to do a further study. The mechanism of rBmpA-induced Lyme arthritis was further studied from the gene expression and protein secretion levels.

The mRNA levels of the two chemokines were positively correlated with rBmpA concentrations as determined by RT-PCR. However, the RT-PCR results showed MCP-5 and MIP-2 gene expression levels in macrophages were not significantly correlated with the time of action of rBmpA; this may be due to rBmpA \'smore predominant promotion of the secretion role in RAW264.7 cells. In addition, it may also be shorter with the mRNA half-life and chemokines in early inflammation of the role of more significant expression of a certain relationship.

The two chemokine levels measured by ELISA showed the same trend as the results of antibody microarray. The two chemokines were significantly increased in cell culture supernatants when macrophages were stimulated by rBmpA; this finding further indicated that rBmpA may be related to the mechanism of Lyme arthritis but also showed the chemokines may be closely related to Lyme arthritis. It was proven that rBmpA could stimulate the secretion of chemokines MCP-5 and MIP-2 in RAW264.7 cells. In summary, we found that the levels of chemokines MCP-5/CCL12 and MIP-2/CXCL2 in mouse macrophage cells were up-regulated by rBmpA in a concentration and time-dependent manner.

Conclusions
===========

Our results showed that the expression levels of the two chemokines in the mouse macrophage RAW264.7 cells were significantly increased after rBmpA stimulation, and the chemokines secreted from BmpA stimulation appear to be closely related to Lyme arthritis.
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![**The relative expression of CXCL2 (MIP-2) mRNA in mouse macrophage RAW264.7 at different time points.** Notes: \* Indicates a significant difference from the negative control in the same times. \* P\<0.05, \*\* P\<0.01, \*\*\* P\<0.001 \#Indicates a significant difference when compared with 10μg/ml rBmpA group at 12h time point. \#P\<0.05, \# \#P\<0.01, \# \# \#P\<0.001 ^▲^ Indicates a significant difference when compared with 20μg/ml rBmpA group at 12h time point. ^▲^P\<0.05, ^▲▲^ P\<0.01, ^▲▲▲^ P\<0.001](ijmsv15p1473g002){#F2}

![**The concentrations of CCL12 (MCP-5) in mouse macrophage supernatants at different time points.** Notes: \* Indicates a significant difference from the negative control in the same times. \* P\<0.05, \*\* P\<0.01, \*\*\* P\<0.001 ● Indicate a significant differences from the 10μg/ml rBmpA control group in the same times. ● P\<0.05, ●● P\<0.01, ●●●P\<0.001 ^▲^ Indicates a significant difference when compared with 20μg/ml rBmpA group at 12h time point. ^▲^P\<0.05, ^▲▲^ P\<0.01, ^▲▲▲^ P\<0.001](ijmsv15p1473g003){#F3}

![**The concentrations of CXCL2 (MIP-2) in mouse macrophage supernatants at different time points.** Notes: \* Indicates a significant difference from the negative control in the same times. \* P\<0.05, \*\* P\<0.01, \*\*\* P\<0.001 ● Indicate a significant differences from the 10μg/ml rBmpA control group in the same times.● P\<0.05, ●● P\<0.01, ●●●P\<0.001 \# Indicates a significant difference when compared with 10μg/ml rBmpA group at 12h time point. \# P\<0.05, \# \# P\<0.01, \# \# \# P\<0.001 ^▲^ Indicates a significant difference when compared with 20μg/ml rBmpA group at 12h time point. ^▲^P\<0.05, ^▲▲^ P\<0.01, ^▲▲▲^ P\<0.001](ijmsv15p1473g004){#F4}

###### 

The results of 25 mouse chemokines detection of cell culture supernatant (pg/ml)

  Chemokine                     12h group                 24h group                                                                                        
  -------------- -------------- ----------- ------------- --------------- --------------- --------------- -- ------------- --------------- --------------- ---------------
  CCL1           TCA-3                      0.4           1.4             0.8             1.0                0.2           1.0             0.9             0.8
  CCL2           MCP-1                      17.6          42.4            33.1            22.3               17.3          79.6            38.6            36.1
  CCL3           MIP-1                      401.7         10259.6         5368.2          8071.8             591.5         8707.8          10058.0         8409.3
  CCL5           RANTES                     16.7          788.3           379.2           463.1              20.2          921.8           419.4           546.5
  CCL9           MIP-1                      2176.6        5147.1          4068.9          4096.0             2091.8        5722.6          4137.5          4221.4
  CCL11          Eotaxin                    2.5           3.5             1.7             1.8                0.4           2.9             4.4             0.9
  [CCL12]{.ul}   [MCP-5]{.ul}               [3.9]{.ul}    [803.4]{.ul}    [145.6]{.ul}    [257.4]{.ul}       [4.2]{.ul}    [1500.9]{.ul}   [232.4]{.ul}    [432.4]{.ul}
  CCL17          TARC                       25.9          26.6            36.5            19.7               7.2           33.8            28.9            29.4
  CCL19          MIP-3                      0.5           0.9             1.2             1.2                0.2           0.9             0.5             1.0
  CCL20          MIP-3                      0.0           3.6             0.8             0.0                0.0           1.7             3.8             0.0
  CCL21          6Ckine                     46.1          27.1            72.4            50.7               42.4          98.4            59.1            63.7
  CCL22          MDC                        40.2          339.4           104.6           129.9              27.3          500.3           111.4           96.8
  CCL24          Eotaxin2                   4.0           10.5            7.2             5.9                2.1           5.8             2.1             7.8
  CCL25          TECK                       455.5         995.0           1065.4          301.6              306.0         918.9           567.9           608.4
  CCL27          CTACK                      484.1         3521.6          1318.4          1948.2             1630.9        2385.1          2328.2          3008.2
  CXCL1          KC                         0.0           0.7             0.0             0.0                0.0           0.0             0.0             0.0
  [CXCL2]{.ul}   [MIP-2]{.ul}               [23.7]{.ul}   [3312.3]{.ul}   [1115.6]{.ul}   [1374.2]{.ul}      [23.2]{.ul}   [3463.1]{.ul}   [1028.0]{.ul}   [1466.7]{.ul}
  CXCL4          PF4                        0.0           41.3            6.2             24.4               8.1           18.0            44.5            12.4
  CXCL5          LIX                        5.9           10.9            8.9             6.8                0.0           13.5            7.7             3.0
  CXCL9          MIG                        55.7          72.2            43.6            53.0               26.2          54.1            105.7           32.2
  CXCL11         I-TAC                      97.3          80.3            111.5           80.0               21.5          113.8           87.3            65.0
  CXCL12         SDF-1a                     0.0           0.7             17.4            0.8                4.4           4.5             0.1             1.4
  CXCL13         BLC                        117.6         121.3           203.2           160.8              146.4         261.0           134.1           200.4
  CXCL16         CXCL16                     2.3           12.7            4.7             7.4                3.9           20.8            6.6             8.7
  CX3CL1         Fractalkine                75.5          119.4           76.2            28.6               55.8          86.3            66.9            14.8
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